Man Group plc Has $676,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Man Group plc increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,954 shares of the biotechnology company's stock after buying an additional 28,481 shares during the quarter. Man Group plc's holdings in BioCryst Pharmaceuticals were worth $676,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BCRX. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the period. Caligan Partners LP boosted its position in BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after acquiring an additional 412,347 shares during the period. Northern Trust Corp boosted its position in BioCryst Pharmaceuticals by 7.7% during the 4th quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after acquiring an additional 143,986 shares during the period. Eversept Partners LP boosted its position in BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after acquiring an additional 1,444,907 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after acquiring an additional 91,998 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BCRX. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC upped their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Trading Down 2.1%

Shares of BioCryst Pharmaceuticals stock traded down $0.23 on Wednesday, reaching $10.56. 3,008,919 shares of the company were exchanged, compared to its average volume of 3,031,304. The stock has a fifty day moving average price of $8.50 and a 200-day moving average price of $8.09. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -17.31 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.92 and a fifty-two week high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 earnings per share. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.